Ahmedabad: The Dholka manufacturing facility of Cadila Pharmaceuticals, a pharmaceutical company, has successfully cleared the US Food and Drug Administration (USFDA) audit yet again.

The Dholka manufacturing facility passed the USFDA audit with nil 483 observations, which signifies compliance and conformance to applicable Current Good Manufacturing Practice (cGMP) regulations enforced by the USFDA. USFDA Inspector Vivin George conducted the facility’s audit from April 3 to 7.

Clearing the USFDA audit with nil 483 observations means Cadila Pharmaceuticals can continue to export its high-quality medicines made at the Dholka manufacturing facility to the US, the world’s largest and most stringent drug market. DeshGujarat